245 related articles for article (PubMed ID: 27476168)
1. Interactions between FGFR2 and RSK2-implications for breast cancer prognosis.
Czaplinska D; Mieczkowski K; Supernat A; Skladanowski AC; Kordek R; Biernat W; Zaczek AJ; Romanska HM; Sadej R
Tumour Biol; 2016 Oct; 37(10):13721-13731. PubMed ID: 27476168
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological significance of β -tubulin isotype III gene expression in breast cancer patients.
He Q; Peng B; Zhuang D; Xiao L; Zheng L; Fan Z; Zhu J; Xu B; Xu C; Zhao J; Wu L; Zhou P; Hou L; Yu F; Zhao G
Cancer Biomark; 2015; 15(6):823-31. PubMed ID: 26406408
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor signalling induces loss of progesterone receptor in breast cancer cells.
Piasecka D; Kitowska K; Czaplinska D; Mieczkowski K; Mieszkowska M; Turczyk L; Skladanowski AC; Zaczek AJ; Biernat W; Kordek R; Romanska HM; Sadej R
Oncotarget; 2016 Dec; 7(52):86011-86025. PubMed ID: 27852068
[TBL] [Abstract][Full Text] [Related]
4. Reduced mRNA expression levels of NFE2L2 are associated with poor outcome in breast cancer patients.
Wolf B; Goebel G; Hackl H; Fiegl H
BMC Cancer; 2016 Oct; 16(1):821. PubMed ID: 27770790
[TBL] [Abstract][Full Text] [Related]
5. Low prognostic implication of fibroblast growth factor family activation in triple-negative breast cancer subsets.
Lee HJ; Seo AN; Park SY; Kim JY; Park JY; Yu JH; Ahn JH; Gong G
Ann Surg Oncol; 2014 May; 21(5):1561-8. PubMed ID: 24385208
[TBL] [Abstract][Full Text] [Related]
6. Increased expression of fibroblastic growth factor receptor 2 is correlated with poor prognosis in patients with breast cancer.
Sun S; Jiang Y; Zhang G; Song H; Zhang X; Zhang Y; Liang X; Sun Q; Pang D
J Surg Oncol; 2012 Jun; 105(8):773-9. PubMed ID: 22006548
[TBL] [Abstract][Full Text] [Related]
7. Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells.
Stratford AL; Fry CJ; Desilets C; Davies AH; Cho YY; Li Y; Dong Z; Berquin IM; Roux PP; Dunn SE
Breast Cancer Res; 2008; 10(6):R99. PubMed ID: 19036157
[TBL] [Abstract][Full Text] [Related]
8. [Abnormal expression of RSK-4 and its clinical significance in breast cancer].
Liu JL; Yang HW; Chen ZS; Jiang Y
Zhonghua Zhong Liu Za Zhi; 2011 Jun; 33(6):452-6. PubMed ID: 21875487
[TBL] [Abstract][Full Text] [Related]
9. Negligible nuclear FOXP3 expression in breast cancer epithelial cells compared with FOXP3-positive T cells.
Droeser RA; Obermann EC; Wolf AM; Wallner S; Wolf D; Tzankov A
Clin Breast Cancer; 2013 Aug; 13(4):264-70. PubMed ID: 23829892
[TBL] [Abstract][Full Text] [Related]
10. The impact of angio-associated migratory cell protein (AAMP) on breast cancer cells in vitro and its clinical significance.
Yin Y; Sanders AJ; Jiang WG
Anticancer Res; 2013 Apr; 33(4):1499-509. PubMed ID: 23564791
[TBL] [Abstract][Full Text] [Related]
11. The Clinical Implications of RSK1-3 in Human Breast Cancer.
Zhao H; Martin TA; Davies EL; Ruge F; Yu H; Zhang Y; Teng XU; Jiang WG
Anticancer Res; 2016 Mar; 36(3):1267-74. PubMed ID: 26977024
[TBL] [Abstract][Full Text] [Related]
12. MiR-4728-3p could act as a marker of HER2 status.
Li H; Zhou X; Zhu J; Cheng W; Zhu W; Shu Y; Liu P
Cancer Biomark; 2015; 15(6):807-14. PubMed ID: 26406406
[TBL] [Abstract][Full Text] [Related]
13. Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers.
Stratford AL; Reipas K; Hu K; Fotovati A; Brough R; Frankum J; Takhar M; Watson P; Ashworth A; Lord CJ; Lasham A; Print CG; Dunn SE
Stem Cells; 2012 Jul; 30(7):1338-48. PubMed ID: 22674792
[TBL] [Abstract][Full Text] [Related]
14. Phosphorylation of RSK2 at Tyr529 by FGFR2-p38 enhances human mammary epithelial cells migration.
Czaplinska D; Turczyk L; Grudowska A; Mieszkowska M; Lipinska AD; Skladanowski AC; Zaczek AJ; Romanska HM; Sadej R
Biochim Biophys Acta; 2014 Nov; 1843(11):2461-70. PubMed ID: 25014166
[TBL] [Abstract][Full Text] [Related]
15. Potential prognostic biomarker CD73 regulates epidermal growth factor receptor expression in human breast cancer.
Zhi X; Wang Y; Yu J; Yu J; Zhang L; Yin L; Zhou P
IUBMB Life; 2012 Nov; 64(11):911-20. PubMed ID: 23086814
[TBL] [Abstract][Full Text] [Related]
16. miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.
Vos S; Vesuna F; Raman V; van Diest PJ; van der Groep P
Oncotarget; 2015 Oct; 6(31):32115-37. PubMed ID: 26378051
[TBL] [Abstract][Full Text] [Related]
17. Decreased expression of SOX17 is associated with tumor progression and poor prognosis in breast cancer.
Fu DY; Tan HS; Wei JL; Zhu CR; Jiang JX; Zhu YX; Cai FL; Chong MH; Ren CL
Tumour Biol; 2015 Sep; 36(10):8025-34. PubMed ID: 25971583
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer.
Van den Eynden GG; Van Laere SJ; Van der Auwera I; Merajver SD; Van Marck EA; van Dam P; Vermeulen PB; Dirix LY; van Golen KL
Breast Cancer Res Treat; 2006 Feb; 95(3):219-28. PubMed ID: 16244790
[TBL] [Abstract][Full Text] [Related]
19. Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer.
Lanigan F; McKiernan E; Brennan DJ; Hegarty S; Millikan RC; McBryan J; Jirstrom K; Landberg G; Martin F; Duffy MJ; Gallagher WM
Int J Cancer; 2009 May; 124(9):2088-97. PubMed ID: 19142967
[TBL] [Abstract][Full Text] [Related]
20. HER2 Codon 655 (Ile/Val) Polymorphism and Breast Cancer in Austrian Women.
Watrowski R; Castillo-Tong DC; Wolf A; Schuster E; Fischer MB; Speiser P; Zeillinger R
Anticancer Res; 2015 Nov; 35(11):5901-4. PubMed ID: 26504013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
